AI assists diagnoses of DR and DME in diabetes and over ten commonly seen ocular fundus abnormalities in the general public. It also assists the decision-making of non-ophthalmologist physicians to improve the examination rate of ocular fundus disease, enabling early screening and treatment, thus protecting public health.

This is the World's first product that auto-detects four types of lesions and two types of anatomical landmarks. It's also Taiwan's first AI grade II medical device which provides both CADx/CADe.